Information Provided By:
Fly News Breaks for February 19, 2020
Feb 19, 2020 | 07:31 EDT
Nomura Instinet analyst Christopher Marai raised the firm's price target on Incyte to $116 from $111 and keeps a Buy rating on the shares. The analyst views the company's Q4 update favorably, and sees "clear paths to success" and "rebirth" of the Incyte as a strong player in the derm space.